Loading
A phase 2 trial of Pamidronate, Thalidomide and Zoledronic acid in Multiple myeloma, run by University of Arkansas, completed.
Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and Thalidomide is a phase 2 interventional study registered as NCT00083382 by University of Arkansas, with 83 participants recorded, started 1998-12 and reaching its primary completion in 2014-05. Interventions recorded: Pamidronate, Thalidomide, Zometa. Conditions recorded: Multiple Myeloma.
Linked to the drug Pamidronate because the registry names it among its interventions and Multiple myeloma among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Pamidronate, Thalidomide, Zoledronic acid, Multiple myeloma and the tag pipeline.
Shares Pamidronate, Multiple myeloma and the tag pipeline.
Shares Zoledronic acid, Multiple myeloma and the tag pipeline.
Shares Smouldering multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Zoledronic acid and the tag pipeline.
Shares Zoledronic acid and the tag pipeline.
Shares Multiple myeloma and the tag pipeline.
Shares Multiple myeloma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/